The ongoing observational study at the Shanghai Mental Health Center aims to elucidate the relationship between miRNA 107 and BACE1 mRNA gene expression in plasma and cerebrospinal fluid of patients with amnestic mild cognitive impairment (aMCI) and normal controls. Given the increasing prevalence of Alzheimer's disease (AD) and the potential for miRNA biomarkers to facilitate early diagnosis, this research could position the sponsor favorably within the growing Alzheimer's diagnostics market. The study's findings may enhance understanding of the molecular underpinnings of aMCI, potentially leading to novel therapeutic targets or diagnostic tools. However, the competitive landscape includes established players in the biomarker space, necessitating careful consideration of differentiation strategies.